Playford MP, Dey AK, Zierold C, et al. - Researchers compared the performance of 1,25-dihydroxyvitaminD (1,25(OH)₂D) vs 25-hydroxyvitamin D (25(OH)D) measurements in capturing cardiovascular risk in psoriasis. They performed FDG PET/CT and CCTA scans in 122 consecutive psoriasis patients at baseline in order to determine visceral adipose volume, aortic vascular uptake of FDG, and coronary plaque burden respectively. Via chemiluminescence, they measured blood levels of both 1,25(OH)₂D and 25(OH)D. Findings revealed the link of low 1,25(OH)₂D levels with visceral adipose volume, vascular uptake of FDG, and coronary plaque burden independent of conventional risk factors—suggesting that the cardiometabolic risk related to vitamin D deficient states may be better captured by 1,25(OH)₂D.